Biodexa Pharmaceuticals Plc (NASDAQ:BDRX – Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 189,600 shares, a growth of 183.8% from the March 31st total of 66,800 shares. Based on an average trading volume of 2,030,000 shares, the short-interest ratio […]
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Biodexa Pharmaceuticals (BDRX) Enters Exclusive License to eRapa streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
26.04.2024 - April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in . Seite 1
Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2023 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.